The FDA approved Corcept Therapeutics’ Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, and the approval arrived nearly four months ahead of schedule. Corcept’s regulator win extends momentum for a glucocorticoid receptor antagonist strategy after earlier FDA miss dynamics in the same drug class.